XMT-2056 is under clinical development by Mersana Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XMT-2056’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XMT-2056 overview

XMT-2056 is under development for the treatment of HER2 expressing solid tumors including HER2 positive breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancers. It is administered through intravenous route. It is developed based on immunosynthen platform. The drug candidate acts by targeting STING and cell expressing HER2

Mersana Therapeutics overview

Mersana Therapeutics (Mersana) is a clinical-stage biopharmaceutical company that develops novel antibody-drug conjugates (ADCs). The company develops drugs using Dolasynthen and Immunosynthen platforms. Its pipeline products include XMT-1660, a B7-H4-targeting multiple solid tumors; XMT-2056, a Novel HER2 Epitope that treats multiple solid tumors, XMT-2068 and XMT-2175. Mersana’s products treat multiple cancer indications including breast, gastric, colorectal and non-small cell lung cancers. The company works in collaboration with Johnson & Johnson and Merck KGaA. Mersana is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of XMT-2056’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.